Formosa Pharmaceuticals was established in 2010. Since 2017, we have acquired from Japan the APNT^® (Active Pharmaceutical Ingredient Nanoparticle Formulation Technology) platform, which offers a wide range of applications, and used this technology to develop early-stage new drug development projects, including APP13007. Through the tireless efforts and innovative spirit of our team, APP13007 successfully achieved positive clinical trial results in the United States and obtained marketing approval in the U.S. in 2024, establishing a foothold in the ophthalmic pharmaceutical field. In the same year, on August 13, 2024, we were officially listed on the Taiwan Stock Exchange, entering a new stage of development. The year 2024 also marks the first year of sustainability for Formosa Pharmaceuticals. We recognize that, beyond meeting ESG requirements set by domestic and international regulations, talent development and corporate sustainability are the essential foundations for Formosa Pharmaceuticals’ long-term success. Our goal is to integrate sustainability into our daily operations by upholding our commitment to quality and innovation. A journey of a thousand miles begins with a single step. Along this path, we remain true to our original aspiration — starting from the role we play in the value chain and advancing steadily to promote more concrete actions toward sustainable development.

Beginning in 2024, Formosa Pharmaceuticals engaged external consultants and conducted ESG knowledge-sharing sessions and training to enable colleagues to understand the disclosure requirements of the ESG Report and the execution details of greenhouse gas inventories. Activity planning also began to incorporate a perspective of co-creating sustainability. We believe that corporate sustainability is an inevitable trend. Beyond legal and regulatory compliance, by contributing additional efforts and considering how we can demonstrate corporate social responsibility, we can lay a strong and enduring foundation for sustainable growth. On the environmental front, we will focus on developing environmentally friendly and energy-saving technologies, striving to reduce carbon emissions and waste generated in the production process throughout the supply chain. Regarding social responsibility, we emphasize product quality and are committed to developing better medicines to improve patients’ quality of life. Internally, we value employee well-being, health, learning, and growth. Externally, Formosa Pharmaceuticals will actively participate in philanthropic initiatives to give back to society. In terms of governance, we adhere to principles of transparency and fairness, establishing a robust internal control mechanism to ensure that company operations are both compliant and efficient. We believe that a sound governance structure is the cornerstone of a company’s long-term and stable development, as well as the key to strengthening investor confidence.

Looking ahead, we will continue to uphold ESG principles and take more solid steps on the path toward sustainable development. We look forward to working together with all of you to create a better tomorrow.